CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project aims to develop new strategies for targeting leukemic stem cells in acute myeloid leukemia. By understanding the interactions between these cells and healthy stem cells, the research seeks to improve treatment outcomes and reduce the side effects associated with current therapies.
Human acute myeloid leukemia (AML) remains a devastating disease with less than 30% of patients surviving five years after diagnosis.
Despite decades of research and detailed mo-lecular insights provided by mutational profiling, curative treatment still requires high-intensity chemotherapy and the crude approach of allogeneic stem cell transplantation – an effective, yet non-specific immunotherapy that is costly to the patient because of its severe side effects.
One reason why the wealth of mole…
EBERHARD KARLS UNIVERSITAET TUEBINGEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Switzerland, Basel
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Switzerland, Basel
Type: Public body
Activity type: Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 keywords.
